RSPI (RespireRx Pharmaceuticals) Net Margin %: 0.00% (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals Net Margin %?

RespireRx Pharmaceuticals RSPI 12 Net Margin % is 0.00% as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

Net margin is calculated as Net Income divided by its Revenue. RespireRx Pharmaceuticals's Net Income for the three months ended in Sep. 2023 was $-0.40 Mil. RespireRx Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, RespireRx Pharmaceuticals's net margin for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for RespireRx Pharmaceuticals's Net Margin % or its related term are showing as below:


RSPI's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

RespireRx Pharmaceuticals  (OTCPK:RSPI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

RespireRx Pharmaceuticals Net Margin % Related Terms

RespireRx Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Net Margin % Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RSPI vs CNBX, NAVB, IPIX: Net Margin % Comparison

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RespireRx Pharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Net Margin % falls into.


RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

RespireRx Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-2.103/0
= %

RespireRx Pharmaceuticals's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-0.396/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
RespireRx Pharmaceuticals (RSPI) has a Net Margin % of 0.00% as of Sep. 2023. Net margin is the ratio of total net income to net sales. View historical data on RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' Net Margin % too high?
RespireRx Pharmaceuticals' current Net Margin % is 0.00%. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' Net Margin % compare to CNBX and NAVB?
RespireRx Pharmaceuticals' Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Net Margin % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price